Video: Early iDose TREX Data Show Double-Digit IOP Reduction

Steven R. Sarkisian Jr., MD, reviews early results with the extended-release travoprost implant.

By: Steven R. Sarkisian, Jr., MD

Glaucoma Physician February 20, 2026

Clinical Report: Early iDose TREX Data Show Double-Digit IOP Reduction

Overview

Early results from a study on the iDose TREX, a sustained-release travoprost implant, demonstrate significant intraocular pressure (IOP) reduction in glaucoma patients. The study reported a 44% decrease in IOP at 11 days and a 37% decrease at 6 weeks post-implantation in a small cohort of 10 patients, with no adverse events noted.

Background

The management of intraocular pressure is crucial in glaucoma care to prevent vision loss. Traditional therapies often face challenges related to patient adherence and tolerability. The introduction of sustained-release implants like iDose TREX offers a promising alternative that may enhance treatment outcomes by providing consistent drug delivery.

Data Highlights

Follow-Up Period	Mean IOP (mmHg)	IOP Reduction
Baseline	24.3	-
Day 11	13.5	44% (10.8 mmHg)
Week 6	15.3	37%

Key Findings

The iDose TREX implant showed a 44% reduction in IOP at 11 days post-implantation.
At 6 weeks, the IOP reduction was maintained at 37%.
No adverse events were reported in the early study of 10 patients.
The iDose TREX has double the drug capacity compared to the previously available iDose TR.
This implant is categorized as a procedural pharmaceutical, distinct from minimally invasive glaucoma surgeries (MIGS).
The small sample size of the study limits the generalizability of the findings.

Clinical Implications

The iDose TREX implant may provide a valuable option for patients with glaucoma who struggle with adherence to topical medications. Its ability to significantly lower IOP with a single procedure could improve long-term management of the disease, although further studies are needed to confirm these findings.

Conclusion

The early data on iDose TREX indicate a promising advancement in glaucoma treatment, highlighting its potential for effective IOP management without the complications associated with traditional therapies. However, further studies are necessary to validate these early results and assess long-term efficacy.

PentaVision

Glaucoma Physician